Corin invests further in the US

Corin invests further in the US

Share this story with your network

Corin invests further in the US

Corin Group is pleased to announce two promotions in the USA, further strengthening our team and demonstrating our ongoing commitment to investment in the world’s largest orthopedic market place.

 

John Watson, currently Vice President, US Operations is appointed to the position of President, USA Operations with immediate effect. In this role John will continue his responsibility for Corin’s US division, with his primary focus on business development across the US market.

 

John Gauger, currently USA Marketing Director, is appointed to the position of Vice President, USA Operations taking responsibility for a number of key functions (based in Tampa) to include Finance, Logistics, Customer Services and Marketing.

 

As the fastest growing division within our global organization and following three years of outstanding success with our renewed global hip and knee portfolio, these appointments will provide the vision and strength of leadership to support Corin’s ambitious expansion plans over the next few years.

 

This announcement marks another significant step forward in the US following a number of FDA 510(k) clearances throughout 2011 to 2013, including: ECiMa™, the world’s first highly cross-linked vitamin E polyethylene which is mechanically annealed (helping to reduce wear in a 40mm bearing by 95% compared to a standard 32mm polyethylene bearing); MiniHip™ stem system designed to preserve bone and restore anatomy in both young and active patients, and an advanced fifth generation total knee system, Unity Knee.

 

About Corin

Corin is a world leader in the development, manufacture, and distribution of a wide range of innovative reconstructive orthopedic devices that address the clinical needs of individual patients. Through continued investment in new technologies, new product development and a focused program of surgeon education from the Corin Academy, Corin’s commitment to Responsible Innovation remains a core pillar in our global strategy.

 

 

Enquiries:

 

  • Corin USA, tel: +1 813 977 4469

John Watson – President, USA Operations

 

  • Corin Group, tel: + 44 1285 659 866

Russ Mably – Chief Operating Officer

 

Note to Editors:

 

As a leader in orthopedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company’s dedicated teams share a common commitment to deliver quality orthopedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives.

 

With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin’s product range ensures that each patient receives the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance. Coupling in-house knowledge and experience with the know-how of eminent surgeons, Corin’s portfolio today includes: Trinityä advanced acetabular system; ECiMa™ next generation vitamin E technology; MiniHipä bone conserving hip replacement; TriFit TS™ cementless blade stem;

MetaFixä cementless total hip; TaperFitä cemented total hip; Unity Knee™ fifth generation total knee and Uniglide™ unicompartmental knee.

 

For more information, visit:

 

Leave a Comment

Your email address will not be published. Required fields are marked *

*